Company Overview
Calumet, Inc. operates as a manufacturer, formulator, and marketer of specialty branded products and renewable fuels, serving markets across North America and internationally through its Specialty Products and Solutions, Performance Brands, and Montana/Renewables segments. The company is categorized within the Basic Materials sector and specifically functions in the Specialty Chemicals industry, an environment that requires significant operational expertise and often involves complex supply chain logistics. In terms of scale, Calumet, Inc. maintains a market capitalization of $2.43B and employs approximately 1540 individuals to support its operations. The annual revenue of $4.14B combined with a market cap of $2.43B indicates a mid-to-large enterprise profile, suggesting the company holds a substantial position in its niche markets while managing a workforce large enough to support diverse product lines.
Financial Health
The company reported revenue of $4.14B over the trailing twelve months, yet it recorded a net income of $-33,800,000 and an EBITDA of $227.30M. The significant gap between the $4.14B revenue and the negative net income of $-33,800,000 reveals a cost structure where operating expenses, taxes, and interest costs are substantial enough to erode profitability despite strong top-line sales. Free cash flow stands at $-74,237,504, which indicates that the company is currently consuming cash rather than generating it, thereby limiting its immediate financial flexibility for organic capital expenditures or unplanned opportunities without external funding. The gross margin is 6.3%, while the operating margin is -3.3% and the profit margin is -0.8%, collectively indicating that the business operates with thin gross profitability and faces significant operational leverage challenges that result in a loss before interest and taxes adjustments. On the balance sheet, the company holds $125.10M in cash against $2.46B in debt, and the debt-to-equity ratio is listed as N/A due to the financial structure, suggesting a highly leveraged position where interest obligations likely consume a large portion of operating cash flow. The current ratio is 1.02, which indicates that the company possesses just enough current assets to cover its current liabilities, signaling a tight but manageable short-term liquidity position. Return on Equity is N/A, while Return on Assets is 1.8%, metrics that reveal management is generating modest returns on the asset base but faces hurdles in generating returns sufficient to satisfy equity holders given the capital structure.
Valuation Assessment
The trailing P/E ratio is N/A because the company is reporting a net loss, while the forward P/E is -71.90, a figure that implies the market is pricing in a long path to profitability or is utilizing alternative valuation methodologies given the negative earnings. The price-to-book ratio is -3.32, which indicates that the market is valuing the company at a significant discount relative to its book value, a common characteristic for distressed or turnaround situations where assets may be undervalued on the balance sheet. The price-to-sales ratio is 0.59 and the EV/EBITDA is 22.05, suggesting that investors are willing to pay slightly more than half of annual sales for the revenue stream, while the enterprise value relative to earnings remains elevated due to the negative earnings figure. The stock has traded between a 52-week high of $31.41 and a 52-week low of $7.68, meaning the current price sits significantly below the 52-week high, reflecting the market's caution regarding the company's earnings trajectory and debt load. The beta is 1.04, which means the stock's price volatility is slightly higher than the broader market, indicating that Calumet, Inc. moves in tandem with general market fluctuations but with a marginally increased sensitivity to market swings.
Growth & Income
Revenue growth year-over-year is 9.4%, whereas earnings growth year-over-year is N/A due to the reported net loss, implying that the company is prioritizing revenue expansion and market share growth over immediate profit generation in the current cycle. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests its earnings and cash flow into growth initiatives, such as capacity expansion or product development, rather than distributing income to shareholders. The overall growth and income profile suggests a company in a reinvestment phase where capital is being deployed to drive future revenue streams, with investors relying on potential value appreciation rather than current dividend income. This strategy aligns with the company's position in the specialty chemicals sector, where long-term contracts and recurring revenue from specialty products often require sustained investment in manufacturing capabilities to maintain competitive positioning.